The national task force for COVID-19, constituted by the Indian Council for Medical Research (ICMR), has recommended the use of hydroxychloroquine to treat COVID-19 for a high-risk population.
ICMR directed that the hydroxy-chloroquine should be given to high-risk population asymptomatic healthcare workers. The medication can be used to treat the suspected and confirmed cases of COVID-19 and asymptomatic household contacts of laboratory-confirmed cases. The Drug Controller General of India (DGCI) approved the usage of hydroxychloroquine for restricted use in emergency situations.
Hydroxychloroquine is generally used to treat malaria infections. The medication can be used with other medications to treat particular auto-immune diseases when other medications cannot be used for the treatment. Hydroxy-chloroquine will be effective against Coronavirus in laboratory studies and in-vivo studies. The use in prophylaxis is derived from the available evidence of benefit as treatment and supported by preclinical data. Also, the drug should be given only on the prescription of a registered medical practitioner. The usage of the drug, in the initial days, has been proven efficient by the United States. Italy and South Korea have used the drug to treat COVID-19.